Welcome to our dedicated page for Iteos Therapeutics SEC filings (Ticker: ITOS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
iTeos Therapeutics filings document the public-company record of a clinical-stage biopharmaceutical issuer that developed immuno-oncology product candidates targeting tumor immunology and immunosuppressive pathways. Earlier disclosures covered operating results, clinical programs, collaboration matters, material agreements, shareholder voting matters, governance and capital-structure information for common stock listed under ITOS.
Later filings record completed corporate-status changes, including a tender offer for the company's outstanding common stock with cash consideration and contingent value rights, removal of the common stock from Nasdaq listing and registration, and a Form 15 terminating or suspending Exchange Act reporting obligations. These records also identify the common stock class, remaining holder profile and related material-event disclosures.
Overview The Company disclosed termination of the GSK collaboration and the belrestotug program (GSK Termination Notice dated 2025-05-13; Mutual Termination Agreement dated 2025-07-18 with a $32.0 million settlement payable). On 2025-05-28 the Company announced intent to wind down clinical and operational activities, expected substantially complete in Q3 2025. The registrant reported substantial doubt about its ability to continue as a going concern as of the issuance date of these financial statements (2025-08-06).
Key financials
- Cash and cash equivalents: $207.820 million; short-term investments: $307.610 million; long-term investments: $74.614 million; total assets: $623.083 million.
- Total liabilities: $129.282 million; unrecognized tax benefits: $48.790 million; grants repayable: $6.606 million.
- Six months ended 6/30/2025 net loss: $113.341 million; three months ended 6/30/2025 net loss: $78.729 million; basic net loss per share: $(2.61) six months, $(1.81) quarter.
- Operating highlights: R&D expense $86.314 million YTD; restructuring costs $16.335 million in the quarter; license and collaboration revenue $0 in 2025 vs $35.0 million in H1 2024.
iTeos Therapeutics (ITOS) has signed a definitive Agreement & Plan of Merger (7/18/25) with Concentra Biosciences. Parent launched a tender offer at $10.047 in cash per share plus one non-transferable CVR for each share.
- CVR payments: (i) 100 % of closing net cash above $475 m; (ii) 80 % of net proceeds from a sale/licence of specified legacy programs if a disposition occurs within 6 months post-close and cash is received within 8 years.
- Offer expires 23:59 ET on 8/28/25; may be extended, outside date 10/16/25.
- Key closing conditions: >50 % shares tendered, minimum closing net cash ≥ $475 m, no legal restraints, reps & warranties accurate. No financing condition; Tang Capital provides a limited guaranty up to $465 m.
- iTeos board unanimously recommends tendering; TD Cowen rendered a fairness opinion.
- Termination fee: $8.4 m; expense reimbursement cap $0.5 m.
- Equity treatment: in-the-money options & certain RSUs cashed out (cash + CVR); out-of-the-money options cancelled.
- Golden-parachute estimates: Detheux $4.1 m, Call $1.9 m, Feltquate $1.2 m.
- D&O indemnification maintained 6 yrs; “tail” insurance premium capped at 200 % of current cost.